GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » Beneish M-Score

23andMe Holding Co (23andMe Holding Co) Beneish M-Score : -3.75 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.75 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for 23andMe Holding Co's Beneish M-Score or its related term are showing as below:

ME' s Beneish M-Score Range Over the Past 10 Years
Min: -4.44   Med: -3.06   Max: 6.9
Current: -3.75

During the past 4 years, the highest Beneish M-Score of 23andMe Holding Co was 6.90. The lowest was -4.44. And the median was -3.06.


23andMe Holding Co Beneish M-Score Historical Data

The historical data trend for 23andMe Holding Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

23andMe Holding Co Beneish M-Score Chart

23andMe Holding Co Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Beneish M-Score
- - 2.05 -3.55

23andMe Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.11 -3.55 -3.00 -4.44 -3.75

Competitive Comparison of 23andMe Holding Co's Beneish M-Score

For the Diagnostics & Research subindustry, 23andMe Holding Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


23andMe Holding Co's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's Beneish M-Score falls into.



23andMe Holding Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of 23andMe Holding Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1117+0.528 * 1.0159+0.404 * 0.8607+0.892 * 0.806+0.115 * 1.0285
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1689+4.679 * -0.216995-0.327 * 1.3312
=-3.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $24.0 Mil.
Revenue was 44.747 + 49.999 + 60.864 + 92.377 = $248.0 Mil.
Gross Profit was 19.936 + 21.729 + 30.68 + 39.982 = $112.3 Mil.
Total Current Assets was $310.0 Mil.
Total Assets was $608.2 Mil.
Property, Plant and Equipment(Net PPE) was $81.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $31.9 Mil.
Selling, General, & Admin. Expense(SGA) was $216.5 Mil.
Total Current Liabilities was $144.1 Mil.
Long-Term Debt & Capital Lease Obligation was $70.4 Mil.
Net Income was -277.976 + -75.27 + -104.624 + -64.098 = $-522.0 Mil.
Non Operating Income was -200.274 + -2.509 + -3.884 + 0.174 = $-206.5 Mil.
Cash Flow from Operations was -12.061 + -57.119 + -69.355 + -44.961 = $-183.5 Mil.
Total Receivables was $26.8 Mil.
Revenue was 66.94 + 75.659 + 64.513 + 100.559 = $307.7 Mil.
Gross Profit was 30.751 + 38.273 + 25.49 + 47.057 = $141.6 Mil.
Total Current Assets was $508.7 Mil.
Total Assets was $1,024.7 Mil.
Property, Plant and Equipment(Net PPE) was $90.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $37.2 Mil.
Selling, General, & Admin. Expense(SGA) was $229.8 Mil.
Total Current Liabilities was $200.1 Mil.
Long-Term Debt & Capital Lease Obligation was $71.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(24.021 / 247.987) / (26.808 / 307.671)
=0.096864 / 0.087132
=1.1117

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(141.571 / 307.671) / (112.327 / 247.987)
=0.460138 / 0.452955
=1.0159

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (309.959 + 81.008) / 608.211) / (1 - (508.671 + 90.778) / 1024.654)
=0.357185 / 0.414974
=0.8607

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=247.987 / 307.671
=0.806

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(37.194 / (37.194 + 90.778)) / (31.911 / (31.911 + 81.008))
=0.290642 / 0.282601
=1.0285

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(216.531 / 247.987) / (229.822 / 307.671)
=0.873155 / 0.746973
=1.1689

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((70.441 + 144.139) / 608.211) / ((71.441 + 200.113) / 1024.654)
=0.352805 / 0.26502
=1.3312

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-521.968 - -206.493 - -183.496) / 608.211
=-0.216995

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

23andMe Holding Co has a M-score of -3.75 suggests that the company is unlikely to be a manipulator.


23andMe Holding Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


23andMe Holding Co (23andMe Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Executives
Kathy L Hibbs officer: See Remarks C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards officer: Head of Therapeutics Discovery 160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage officer: Interim CFO 490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan officer: Head of Therapeutics C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell director, officer: Chief Financial Officer 27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md director BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson officer: VP, General Manager-Consumer 440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim officer: See Remarks 6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon officer: Vice President, Engineering 1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch officer: See Remarks 2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler officer: Vice President, People 1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p. 10 percent owner 2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc 10 percent owner 171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki director, 10 percent owner, officer: Chief Executive Officer C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606